Physician profile
Ashley B Pullen
NPI 1942400403
$11,116.86
in general payments reported to CMS, 2019-2025
52 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,978 · 2020: $1,980 · 2021: $2,035 · 2022: $1,587 · 2023: $1,353 · 2024: $1,070 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,537.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,912.70 | 2019-2025 | |
| Pfizer INC. | $1,125.37 | 2019-2025 | |
| Novo Nordisk INC | $784.37 | 2019-2025 | Rybelsus, Ozempic, Tresiba |
| Astrazeneca Pharmaceuticals Lp | $631.20 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $568.94 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Allergan, INC. | $541.06 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $519.75 | 2019-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $506.46 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $483.51 | 2019-2025 | Kisunla, Mounjaro, Emgality |
| Glaxosmithkline, LLC. | $429.09 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amarin Pharma, INC. | $406.55 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $282.49 | 2019-2025 | Jardiance, Synjardy, Trijardy Xr |
| Amgen INC. | $259.34 | 2019-2022 | |
| Esperion Therapeutics, INC. | $221.53 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $206.99 | 2020-2021 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Pullen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.